(Press-News.org) CHICAGO – Although approved for use for treating traumatic brain injury (TBI) in nearly 60 countries, use of citicoline in a randomized trial that included more than 1,200 participants with TBI did not result in improvement in functional and cognitive status, according to a study appearing in the November 21 issue of JAMA.
"Despite considerable advances in emergency and critical care management of TBI as well as decades of research on potential agents for neuroprotection or enhanced recovery, no effective pharmacotherapy has yet been identified," according to background information in the article. Citicoline, an endogenous (produced within the body) compound, offers potential neuroprotective properties as well as neurorepair post injury. Citicoline is widely available in the United States as a nutraceutical (product that reportedly provides health and medical benefits) and is used by patients with a range of neurologic disorders, yet it has not been evaluated in a large randomized clinical trial for TBI.
Ross D. Zafonte, D.O., of Harvard Medical School, Spaulding Rehabilitation and Massachusetts General Hospital, Boston, and colleagues conducted a study to evaluate the efficacy of citicoline for improving cognitive and functional status among patients with TBI. The Citicoline Brain Injury Treatment Trial (COBRIT), a phase 3, randomized clinical trial, was conducted between July 2007 and February 2011. The study, which included 1,213 patients at 8 U.S. level 1 trauma centers, examined the effects of 90 days of enteral or oral citicoline (2,000 mg) vs. placebo initiated within 24 hours of injury in patients with complicated mild, moderate, and severe TBI.
The researchers found that the citicoline and placebo groups did not differ significantly at the 90-day evaluation on measures of cognitive and functional status. "Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4 percent in the citicoline group and 35.6 percent in the placebo group. For all other scales the rate of improvement ranged from 37.3 percent to 86.5 percent in the citicoline group and from 42.7 percent to 84.0 percent in the placebo group."
There was no significant treatment effect in the two severity subgroups (moderate/severe and complicated mild TBI). In patients with moderate/severe TBI, no statistically significant difference was observed between treatment groups at the 180-day evaluation.
The overall proportion of patients reporting serious adverse events was similar between the placebo and citicoline groups.
"The COBRIT study indicates that citicoline was not superior to placebo as an acute and postacute therapy among participants with a broad range of severity of TBI. The worldwide use of citicoline for TBI should now be questioned."
(JAMA. 2012;308(19):1993-2000; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Effective Treatment of Traumatic Brain Injury - Learning From Experience
In an accompanying editorial, Robert L. Ruff, M.D., Ph.D., and Ronald G. Riechers II, M.D., of the Cleveland VA Medical Center, and Case Western Reserve University (Dr. Ruff), write that the primary importance reported by this trial "is that it conclusively demonstrated the lack of efficacy of citicoline monotherapy for TBI."
"It is unlikely that this finding can be accounted for by limitations in the study design or conduct. The broader implication of the COBRIT study may be that no single therapeutic agent is likely to be sufficient to improve functional outcomes for patients with TBI. The diverse and complex nature of the pathological mechanisms activated by TBI suggests that multimodal treatment interventions may be needed to improve recovery. Future studies of TBI treatment should be designed to incorporate multiple treatment interventions and comprehensive TBI rehabilitation strategies, either as components of the intervention or standardized across study treatment groups."
(JAMA. 2012;308(19):2032-2033; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of interest and none were reported.
###
To contact Ross D. Zafonte, D.O., call Tim Sullivan at 617-573-2918 or email tsullivan11@partners.org. To contact editorial co-author Robert L. Ruff, M.D., Ph.D., call Jessica Studeny at 216-368-4692 or email jessica.studeny@case.edu.
END
A rapid test for tuberculosis (TB) could help to reduce TB deaths, improve TB treatment, and also offer reasonably good value for money if introduced in southern Africa, an area that has high rates of HIV and a type of TB that is resistant to some drugs (multi-drug resistant TB), according to a study published in this week's PLOS Medicine.
The World Health Organization (WHO) recently recommended the use of a new diagnostic test for TB (the Xpert MTB/RIF test), which can show a result within 2 hours, in people at high risk of multi-drug resistant TB and/or HIV-associated ...
Models used for predicting the likelihood of individuals developing chronic kidney disease and for predicting disease progression in people who already have the condition are useful tools but not yet robust enough to help inform clinical guidelines, according to a study published in this week's PLOS Medicine.
Chronic kidney disease is a common but serious condition which can lead to kidney failure. The condition cannot be cured but progression of the disease can be slowed by controlling high blood pressure and diabetes, both causes of chronic kidney disease, and by adopting ...
In this week's PLOS Medicine, Charles Weijer and colleagues present the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials, which aims to provide researchers and research ethics committees with detailed guidance on the ethical design, conduct, and review of CRTs.
###
Funding: This work was supported by the Canadian Institutes of Health Research (grant numbers MOP85066, MOP89790). CW and JMG hold Tier I Canada Research Chairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the ...
New drugs derived from components of a specific diet used by children with severe, drug-resistant epilepsy could offer a new treatment, according to research published today in the journal Neuropharmacology.
Scientists from Royal Holloway, in collaboration with University College London, have identified specific fatty acids that have potent antiepileptic effects, which could help control seizures in children and adults.
The discovery could lead to the replacement of the ketogenic diet, which is often prescribed for children with severe drug-resistant epilepsy. The ...
Scientists from Queen Mary, University of London have sequenced the genetic code of a birch tree for the first time, which could help protect British birch populations.
The genome, which is around 450 million letters, will help researchers understand the genetic basis of traits such as disease resistance and growth shape.
There are over sixty species of birch trees around the world, with huge ecological and commercial importance. They are an essential part of the Boreal forest located around the North Pole, which is the world's largest land-based ecosystem. The team ...
It appears that it's not just us Brits who are fascinated with the UK weather.
A group of researchers from Germany has taken to investigating the potential changes in extreme rainfall patterns across the UK as a result of future global warming and has found that in some regions, the time of year when we see the heaviest rainfall is set to shift.
The study, published today, 21 November, in IOP Publishing's journal Environmental Research Letters, finds that between 2061 and 2100, the south-east of the country will likely experience its most extreme rainfall later in the ...
Research: Muscular strength in male adolescents and premature death: cohort study of one million participants
Low muscle strength in adolescence is strongly associated with a greater risk of early death from several major causes, suggests a large study published on bmj.com today.
The effect is similar to well established risk factors for early death like being overweight or having high blood pressure, leading the authors to call for young people, particularly those with very low strength, to engage in regular physical activity to boost their muscular fitness.
High ...
Research: General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis
Editorial: The value of conducting periodic health checks
Researchers have found that routine general health checks, which have become common practice in some countries, do not reduce the number of deaths from cardiovascular disease or cancer. They do, however, increase the number of new diagnoses.
Health checks were defined as screening for more than one disease or risk factor in more than one organ system offered to a general ...
How flowers have evolved particular colours, shapes and scents to attract pollinators has long fascinated ecologists. Now, using artificial flowers and high-speed video, researchers have gained intriguing insights into the intimate relationship between hummingbirds and the flowers they pollinate. The study, published in the British Ecological Society's journal Functional Ecology, is the first to measure how much energy hummingbirds use while hovering to feed from flowers of different orientation.
Hummingbirds are among the smallest and most brightly-coloured birds on Earth, ...
Research: Sharing of clinical trial data among trialists: a cross sectional survey
Nearly nine out of ten clinicians carrying out biomedical research trials believe that trial data should be shared more easily, even though they do express some practical concerns, a study published today on bmj.com reveals.
BMJ has long championed transparency in medical research. Last month, the journal launched an open data campaign to compel greater accountability in healthcare, and from January 2013, it will require a commitment from trialists to make their data available on reasonable ...
